The short version of Melanotan II fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-02 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
== Components == Honey bee venom is a complex mixture of proteins and smaller molecules. The main component is melittin, which amounts to 52% of venom peptides. One of the main allergens is phospholipase A2, which amounts to 12% and is an enzyme that catalyzes the hydrolysis of phospholipids, causing degradation of cell membranes, causing cell death. Adolapin contributes 2–5% of the peptides. Further protein components include apamin (2%), a neurotoxin, hyaluronidase (2%), which dilates blood vessels, increasing their permeability and facilitating the spread of the venom, mast cell degranulating peptide (2%), tertiapin, and secapin. Small molecules in bee venom include histamine (0.1–1%), dopamine and noradrenaline.
West Germany was the common English name for the Federal Republic of Germany (FRG) from its formation on 23 May 1949 until its reunification with East Germany on 3 October 1990. It was sometimes known as the Bonn Republic after its capital city of Bonn, or as the Second German Republic. During the Cold War, the western portion of Germany and the associated territory of West Berlin were parts of the Western Bloc. West Germany was formed as a political entity during the Allied occupation of Germany after World War II, established from twelve states formed in the three Allied zones of occupation held by the United States, the United Kingdom, and France. At the onset of the Cold War, Europe was divided between the Western and Eastern blocs. Germany was divided into the two countries. Initially, West Germany claimed an exclusive mandate for all of Germany, representing itself as the sole democratically reorganised continuation of the 1871–1945 German Reich. Three southwestern states of West Germany merged to form Baden-Württemberg in 1952, and the Saarland joined West Germany as a state in 1957 after it had been separated as the Saar Protectorate from Allied-occupied Germany by France (the separation had not been legal as it had not been recognised by the Allied Control Council). In addition to the resulting ten states, West Berlin was considered an unofficial de facto eleventh state.
==== MeSH D12.776.377.715.085 – alpha-globulins ==== MeSH D12.776.377.715.085.050 – alpha 1-antichymotrypsin MeSH D12.776.377.715.085.085 – alpha 1-antitrypsin MeSH D12.776.377.715.085.100 – alpha-macroglobulins MeSH D12.776.377.715.085.118 – antiplasmin MeSH D12.776.377.715.085.125 – antithrombin iii MeSH D12.776.377.715.085.214 – ceruloplasmin MeSH D12.776.377.715.085.394 – haptoglobins MeSH D12.776.377.715.085.450 – heparin cofactor ii MeSH D12.776.377.715.085.640 – orosomucoid MeSH D12.776.377.715.085.740 – progesterone-binding globulin MeSH D12.776.377.715.085.750 – retinol-binding proteins MeSH D12.776.377.715.085.901 – transcortin
Sources: en.wikipedia.org
== Products == It designs and manufactures automatic machines for the processing and packaging of pharmaceuticals, cosmetics, tea and coffee. It specializes in tea bagging and coffee pod machines, solid dose manufacturing, sterile processing equipment, liquid filling, freeze-drying, labelling, blistering, counting, tube filling, end-of-line and cartoning machines.
== Treatment == Management of acanthosis nigricans (AN) generally involves evaluating for and addressing any associated underlying condition rather than treating the skin changes alone. When AN occurs in the setting of obesity, insulin resistance or type 2 diabetes mellitus, improvement in metabolic status may be followed by gradual softening or lightening of the lesions, although the degree of change varies. Drug-induced AN may improve after reduction or discontinuation of the causative medication when clinically appropriate. Reported associations include systemic corticosteroids, high-dose nicotinic acid and certain hormonal therapies. In malignancy-associated AN, particularly that linked to gastrointestinal adenocarcinomas, regression of the cutaneous changes has been observed following treatment of the underlying tumour, though this is not universal. Sudden onset, rapid progression or mucosal involvement have been described in malignant forms and may prompt further evaluation.
Most teleost species are oviparous, having external fertilisation with both eggs and sperm being released into the water for fertilisation. Internal fertilisation occurs in 500 to 600 species of teleosts but is more typical for Chondrichthyes and many tetrapods. This involves the male inseminating the female with an intromittent organ. Fewer than one in a million of externally fertilised eggs survives to develop into a mature fish, but there is a much better chance of survival among the offspring of members of about a dozen families which are viviparous. In these, the eggs are fertilised internally and retained in the female during development. Some of these species, like the live-bearing aquarium fish in the family Poeciliidae, are ovoviviparous; each egg has a yolk sac which nourishes the developing embryo, and when this is exhausted, the egg hatches and the larva is expelled into the water column. Other species, like the splitfins in the family Goodeidae, are fully viviparous, with the developing embryo nurtured from the maternal blood supply via a placenta-like structure that develops in the uterus. Oophagy is practised by a few species, such as Nomorhamphus ebrardtii; the mother lays unfertilised eggs on which the developing larvae feed in the uterus, and intrauterine cannibalism has been reported in some halfbeaks. There are two major reproductive strategies of teleosts; semelparity and iteroparity. In the former, an individual breeds once after reaching maturity and then dies.
Sources: en.wikipedia.org
1962 Waksman Merck postdoc fellowship, USA. 1967 Humboldt assistant professorship stipend at the Max-Planck Institute, Munich, Germany. 1970 visiting professorship at the Weizmann Institute of Science, Rehovot, Israel. 1973 guest professorship in Dallas, Texas, USA. 1978 guest professorship (Japan Society for the Promotion of Science) in Japan. 1982–1986 Full Professor (Ordinarius) in biotechnology at The Federal Institute of technology, ETH Zurich, Switzerland. 1993 honorary visiting professorship in biochemistry at the University of Bath, UK. 1995 honorary visiting professorship in biochemistry at the Université Catholique de Louvain, Louvain-la-Neuve, Belgium. During these stays he collaborated with Nobel Prize winners Lynen, Waksman as well as with Professors Estabrook and Srere, Katchalski-Katzir and Wilchek, Fukui, Chibata, Suzuki, Rees and Creighton respectively.
=== Fetal blood supply === In the growing fetus, a major source of blood to the liver is the umbilical vein, which supplies nutrients to the growing fetus. The umbilical vein enters the abdomen at the umbilicus and passes upward along the free margin of the falciform ligament of the liver to the inferior surface of the liver. There, it joins with the left branch of the portal vein. The ductus venosus carries blood from the left portal vein to the left hepatic vein and then to the inferior vena cava, allowing placental blood to bypass the liver. In the fetus, the liver does not perform the normal digestive processes and filtration of the infant liver because nutrients are received directly from the mother via the placenta. The fetal liver releases some blood stem cells that migrate to the fetal thymus, creating the T cells (or T lymphocytes). After birth, the formation of blood stem cells shifts to the red bone marrow. After 2–5 days, the umbilical vein and ductus venosus are obliterated; the former becomes the round ligament of liver and the latter becomes the ligamentum venosum. In the disorders of cirrhosis and portal hypertension, the umbilical vein can open up again. Unlike eutherian mammals, in marsupials the liver remains haematopoietic well after birth.
phase transition 1. A transformation of a chemical substance between solid, liquid, and gaseous states of matter and, in rare cases, plasma. 2. The measurable values of the external conditions at which such a transformation occurs.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.